Microbiota Dynamics in Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

被引:119
|
作者
Song, Yang [1 ]
Garg, Shashank [2 ]
Girotra, Mohit [2 ]
Maddox, Cynthia [1 ]
von Rosenvinge, Erik C. [3 ]
Dutta, Anand [2 ]
Dutta, Sudhir [2 ,4 ]
Fricke, W. Florian [1 ]
机构
[1] Univ Maryland, Sch Med, Inst Genome Sci, Baltimore, MD 21201 USA
[2] Sinai Hosp, Div Gastroenterol, Baltimore, MD 21215 USA
[3] Univ Maryland, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
来源
PLOS ONE | 2013年 / 8卷 / 11期
关键词
GUT MICROBIOTA; INTESTINAL MICROBIOTA; SEQUENCE-ANALYSIS; DISEASE; THERAPY; VANCOMYCIN; COLITIS; DIARRHEA; COMBINATION; SENSITIVITY;
D O I
10.1371/journal.pone.0081330
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clostridium difficile causes antibiotic-associated diarrhea and pseudomembraneous colitis and is responsible for a large and increasing fraction of hospital-acquired infections. Fecal microbiota transplantation (FMT) is an alternate treatment option for recurrent C. difficile infection (RCDI) refractory to antibiotic therapy. It has recently been discussed favorably in the clinical and scientific communities and is receiving increasing public attention. However, short-and long-term health consequences of FMT remain a concern, as the effects of the transplanted microbiota on the patient remain unknown. To shed light on microbial events associated with RCDI and treatment by FMT, we performed fecal microbiota analysis by 16S rRNA gene amplicon pyrosequencing of 14 pairs of healthy donors and RCDI patients treated successfully by FMT. Post-FMT patient and healthy donor samples collected up to one year after FMT were studied longitudinally, including one post-FMT patient with antibiotic-associated relapse three months after FMT. This analysis allowed us not only to confirm prior reports that RCDI is associated with reduced diversity and compositional changes in the fecal microbiota, but also to characterize previously undocumented post-FMT microbiota dynamics. Members of the Streptococcaceae, Enterococcaceae, or Enterobacteriaceae were significantly increased and putative butyrate producers, such as Lachnospiraceae and Ruminococcaceae were significantly reduced in samples from RCDI patients before FMT as compared to post-FMT patient and healthy donor samples. RCDI patient samples showed more case-specific variations than post-FMT patient and healthy donor samples. However, none of the bacterial groups were invariably associated with RCDI or successful treatment by FMT. Overall microbiota compositions in post-FMT patients, specifically abundances of the above-mentioned Firmicutes, continued to change for at least 16 weeks after FMT, suggesting that full microbiota recovery from RCDI may take much longer than expected based on the disappearance of diarrheal symptoms immediately after FMT.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Fecal Microbiota Transplantation for Primary Clostridium difficile Infection
    Juul, Frederik E.
    Garborg, Kjetil
    Bretthauer, Michael
    Skudal, Hilde
    Oines, Mari N.
    Wiig, Havard
    Rose, Oystein
    Seip, Birgitte
    Lamont, J. Thomas
    Midtvedt, Tore
    Valeur, Jorgen
    Kalager, Mette
    Holme, Oyvind
    Helsingen, Lise
    Loberg, Magnus
    Adami, Hans-Olov
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26): : 2535 - +
  • [22] Fecal microbiota transplantation in relapsing Clostridium difficile infection
    Rohlke, Faith
    Stollman, Neil
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2012, 5 (06) : 403 - 420
  • [23] Fecal Microbiota Transplantation for Treatment of Clostridium difficile Infection
    Dai, Cong
    Jiang, Min
    Sun, Ming-jin
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (02) : 171 - 172
  • [24] Fecal microbiota transplantation in treating Clostridium difficile infection
    Brown, William R.
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (08) : 405 - 408
  • [25] Fecal microbiota transplantation for the treatment of Clostridium difficile infection
    Rao, Krishna
    Safdar, Nasia
    [J]. JOURNAL OF HOSPITAL MEDICINE, 2016, 11 (01) : 56 - 61
  • [26] Treating Clostridium difficile Infection With Fecal Microbiota Transplantation
    Bakken, Johan S.
    Borody, Thomas
    Brandt, Lawrence J.
    Brill, Joel V.
    Demarco, Daniel C.
    Franzos, Marc Alaric
    Kelly, Colleen
    Khoruts, Alexander
    Louie, Thomas
    Martinelli, Lawrence P.
    Moore, Thomas A.
    Russell, George
    Surawicz, Christina
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (12) : 1044 - 1049
  • [27] Special Considerations for Fecal Microbiota Transplantation in Pediatric Recurrent Clostridium difficile Infection
    Kellermayer, Richard
    Hollister, Emily B.
    Nagy-Szakal, Dorottya
    Ihekweazu, Faith D.
    Haynes, Abria
    Pitashny, Milena
    Bocchini, Claire E.
    Luna, Ruth A.
    Versalovic, James
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S961 - S962
  • [28] Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis
    Nanki, Kosaku
    Mizuno, Shinta
    Matsuoka, Katsuyoshi
    Ono, Keiko
    Sugimoto, Shinya
    Kiyohara, Hiroki
    Arai, Mari
    Nakashima, Moeko
    Takeshita, Kozue
    Saigusa, Keiichiro
    Senoh, Mitsutoshi
    Fukuda, Tadashi
    Naganuma, Makoto
    Kato, Haru
    Suda, Wataru
    Hattori, Masahira
    Kanait, Takanori
    [J]. INTESTINAL RESEARCH, 2018, 16 (01) : 142 - 146
  • [29] Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
    Hvas, Christian Lodberg
    Jorgensen, Simon Mark Dahl
    Jorgensen, Soren Peter
    Storgaard, Merete
    Lemming, Lars
    Hansen, Mette Mejlby
    Erikstrup, Christian
    Dahlerup, Jens Frederik
    [J]. GASTROENTEROLOGY, 2019, 156 (05) : 1324 - +
  • [30] Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results
    Reigadas, Elena
    Olmedo, Maria
    Valerio, Maricela
    Vazquez-Cuesta, Silvia
    Alcala, Luis
    Marin, Mercedes
    Munoz, Patricia
    Bouza, Emilio
    [J]. REVISTA ESPANOLA DE QUIMIOTERAPIA, 2018, 31 (05) : 411 - 418